Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EGRX 
Eagle Pharmaceuticals Inc (EGRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: EGRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17
1 Year Target Price $17
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.29M USD | Price to earnings Ratio 5 | 1Y Target Price 17 |
Price to earnings Ratio 5 | 1Y Target Price 17 | ||
Volume (30-day avg) 1 | Beta 0.95 | 52 Weeks Range 0.10 - 3.87 | Updated Date 02/26/2026 |
52 Weeks Range 0.10 - 3.87 | Updated Date 02/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.64% | Operating Margin (TTM) 15.94% |
Management Effectiveness
Return on Assets (TTM) 6.63% | Return on Equity (TTM) 4.88% |
Valuation
Trailing PE 5 | Forward PE 11.34 | Enterprise Value 2631510 | Price to Sales(TTM) 0.01 |
Enterprise Value 2631510 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 1.75 | Shares Outstanding 13157553 | Shares Floating 5908682 |
Shares Outstanding 13157553 | Shares Floating 5908682 | ||
Percent Insiders - | Percent Institutions 55.2 |
Upturn AI SWOT
Eagle Pharmaceuticals Inc
Company Overview
History and Background
Eagle Pharmaceuticals Inc. was founded in 2007 and is a specialty pharmaceutical company. The company focuses on developing and commercializing innovative and differentiated injectable and inhalable drug products. A significant milestone was the FDA approval and commercialization of ROLSAu00ae (alteplase) in 2023, a ready-to-use intravenous formulation of alteplase. Eagle Pharmaceuticals has evolved by strategically acquiring and developing late-stage clinical assets with the aim of addressing unmet medical needs and creating value through its development and commercialization expertise.
Core Business Areas
- Product Development and Commercialization: Eagle Pharmaceuticals focuses on the development and commercialization of novel and differentiated injectable and inhalable drug products. This involves identifying promising late-stage clinical assets, optimizing their formulations, navigating the regulatory approval process, and then bringing these products to market.
- Strategic Partnerships and Licensing: The company may engage in strategic partnerships and licensing agreements to advance its pipeline, acquire new assets, or expand its commercial reach.
Leadership and Structure
Eagle Pharmaceuticals Inc. is led by a management team with extensive experience in the pharmaceutical industry. Key leadership roles typically include a Chief Executive Officer (CEO), Chief Financial Officer (CFO), Chief Operating Officer (COO), and heads of research and development, regulatory affairs, and commercial operations. The organizational structure is designed to support efficient product development, regulatory navigation, and market launch.
Top Products and Market Share
Key Offerings
- Competitors: Genoa Pharmaceuticals (tPA),AbbVie (Kogenate FS, but for hemophilia),Various generic manufacturers of alteplase
- Description: RO u099cu09c8Su00ae is a ready-to-use intravenous formulation of alteplase, a thrombolytic drug used to break down blood clots. Its ready-to-use nature aims to simplify administration and reduce preparation time in critical care settings. The market for thrombolytics is competitive, with existing generic and branded formulations.
- Market Share: As a recently approved product, specific market share data is not yet widely available, but it competes in the broader thrombolytic market.
- Product Name: RO u099cu09c8Su00ae (alteplase)
- Competitors: CSL Behring (Haegarda, Berinert),Shire (Firazyr),BioCryst Pharmaceuticals (Orladeyo)
- Description: Kalbitoru00ae is indicated for the acute treatment of acute attacks in adult patients with hereditary angioedema (HAE). It is a plasma kallikrein inhibitor. The market for HAE treatments is specialized and growing.
- Market Share: Eagle Pharmaceuticals acquired exclusive U.S. rights to Kalbitoru00ae from Dyax Corp. in 2020. Specific market share figures are proprietary but it is a key product in the HAE treatment landscape.
- Product Name: Kalbitoru00ae (ecallantide)
- Competitors: Varies depending on the specific therapeutic area and stage of development.
- Description: Eagle Pharmaceuticals has a pipeline of other drug candidates in various stages of development, primarily focusing on novel formulations and delivery systems for existing drugs or new chemical entities.
- Market Share: N/A (pipeline products)
- Product Name: Other Pipeline Products
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by significant research and development investments, stringent regulatory oversight, and a dynamic competitive landscape. Key trends include a focus on specialty drugs, biologics, personalized medicine, and the increasing importance of novel drug delivery systems. The market for injectable and inhalable drugs remains robust due to their efficacy and role in treating acute conditions and chronic diseases.
Positioning
Eagle Pharmaceuticals positions itself as a specialty pharmaceutical company focused on developing and commercializing differentiated drug products. Its competitive advantages lie in its ability to identify and develop late-stage assets, its expertise in formulation and drug delivery, and its strategic approach to navigating the regulatory approval process. The company aims to capture market share by offering products with improved convenience, efficacy, or safety profiles.
Total Addressable Market (TAM)
The TAM for Eagle Pharmaceuticals' products is substantial and varies by therapeutic area. For instance, the thrombolytic market is in the billions of dollars globally, while the rare disease market, such as for HAE, is smaller but highly specialized. Eagle Pharmaceuticals is positioned to address segments within these larger markets by offering innovative solutions. Its strategy focuses on capturing a meaningful share of these specific therapeutic niches rather than aiming for broad market dominance across all pharmaceutical areas.
Upturn SWOT Analysis
Strengths
- Expertise in developing differentiated injectable and inhalable drug products.
- Strong regulatory affairs and drug development capabilities.
- Focus on late-stage clinical assets with potential for near-term commercialization.
- Acquisition of established products like Kalbitoru00ae to generate revenue.
- Recent approval and launch of a key product (RO u099cu09c8Su00ae).
Weaknesses
- Reliance on a limited number of key products and pipeline candidates.
- Potential challenges in manufacturing and supply chain for new products.
- Significant R&D expenses and the inherent risks associated with drug development.
- Dependence on strategic partnerships and licensing for pipeline expansion.
- May have limited commercial infrastructure compared to larger pharmaceutical companies.
Opportunities
- Expansion of product indications or geographies for existing and pipeline products.
- Strategic acquisitions of complementary technologies or product portfolios.
- Partnerships with larger pharmaceutical companies for co-promotion or distribution.
- Growing demand for convenient and innovative drug delivery systems.
- Addressing unmet medical needs in specific therapeutic areas.
Threats
- Competition from established pharmaceutical companies and generic manufacturers.
- Regulatory hurdles and potential delays in product approvals.
- Patent expirations and the introduction of biosimilars or generics.
- Changes in healthcare reimbursement policies and pricing pressures.
- Adverse clinical trial results or post-market safety issues.
Competitors and Market Share
Key Competitors
- Genoa Pharmaceuticals (US Stock Symbol: GNO)
- AbbVie Inc. (US Stock Symbol: ABBV)
- CSL Limited (OTC: CSLYY)
- Shire (now part of Takeda Pharmaceutical Company Limited - US Stock Symbol: Takeda)
- BioCryst Pharmaceuticals, Inc. (US Stock Symbol: BCRX)
Competitive Landscape
Eagle Pharmaceuticals faces a competitive landscape populated by large, established pharmaceutical companies with extensive resources and smaller, specialized biopharmaceutical firms. Its advantages lie in its focused approach to developing niche products and its agility in navigating the development and regulatory pathway. However, it must contend with the significant market presence and financial power of larger competitors, as well as the potential for new entrants and the pricing pressures common in the pharmaceutical industry.
Growth Trajectory and Initiatives
Historical Growth: Eagle Pharmaceuticals' historical growth has been shaped by its strategy of acquiring and developing late-stage drug candidates. Growth has likely been punctuated by key development milestones, regulatory approvals, and product launches. Revenue streams have evolved as new products enter the market.
Future Projections: Future projections for Eagle Pharmaceuticals depend on the successful development and commercialization of its pipeline products, particularly RO u099cu09c8Su00ae and any other emerging candidates. Analyst estimates would consider market penetration rates, competitive responses, and the company's ability to expand its product portfolio. Growth is anticipated to be driven by increasing sales of its marketed products and potential new approvals.
Recent Initiatives: Recent initiatives include the FDA approval and launch of RO u099cu09c8Su00ae (alteplase), the acquisition of U.S. rights to Kalbitoru00ae, and ongoing research and development efforts for its pipeline products. The company continues to explore strategic opportunities to enhance its product portfolio and commercial capabilities.
Summary
Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company with a focused strategy on developing and commercializing differentiated injectable and inhalable drugs. The recent launch of RO u099cu09c8Su00ae is a significant step, complementing its existing product Kalbitoru00ae. While the company demonstrates strength in regulatory expertise and development, it faces challenges related to reliance on a few key products and intense competition. Future growth hinges on successful pipeline execution and market penetration against well-established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Eagle Pharmaceuticals Inc. official investor relations website
- SEC filings (10-K, 10-Q)
- Financial news outlets and market data providers (e.g., Bloomberg, Reuters, Yahoo Finance)
- Industry analysis reports
Disclaimers:
This JSON output is generated based on publicly available information and is intended for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. Market share data is an estimation and may not reflect exact current figures. The AI-based rating is an automated assessment and should not be the sole basis for investment decisions. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eagle Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Woodcliff Lake, NJ, United States | ||
IPO Launch date 2014-02-12 | CEO & Chairman Mr. Michael Graves | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 134 | Website https://www.eagleus.com |
Full time employees 134 | Website https://www.eagleus.com | ||
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.